Biomea Fusion, Inc. Research and Development Expense
Biomea Fusion, Inc. (BMEA) reported Research and Development Expense of $9.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Biomea Fusion, Inc. research and development expense for the quarter ending 2026-06-30 was $9.14M, a 44.81% decline year-over-year.
- Biomea Fusion, Inc. research and development expense for the quarter ending 2026-03-31 was $9.12M, a 60.17% decline year-over-year.
- Biomea Fusion, Inc. research and development expense for the quarter ending 2025-12-31 was $8.12M, a 67.85% decline year-over-year.
- Biomea Fusion, Inc. research and development expense for the quarter ending 2025-09-30 was $14.40M, a 47.14% decline year-over-year.
- Biomea Fusion, Inc. research and development expense for fiscal 2025 was $61.98M, a 47.51% decline from fiscal 2024.
- Biomea Fusion, Inc. research and development expense for fiscal 2024 was $118.08M, a 15.15% increase from fiscal 2023.
- Biomea Fusion, Inc. research and development expense for fiscal 2023 was $102.55M, a 63.52% increase from fiscal 2022.
- Biomea Fusion, Inc. research and development expense for fiscal 2022 was $62.71M, a 124.01% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.14M 10-Q · filed 2026-08-05 | $18.26M 10-Q · filed 2026-08-05 | $26.38M derived: sum of 3 quarters · filed 2026-08-05 | $40.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $9.12M 10-Q · filed 2026-05-11 | $17.23M derived: sum of 2 quarters · filed 2026-05-11 | $31.64M derived: sum of 3 quarters · filed 2026-05-11 | $48.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $8.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $22.52M derived: sum of 2 quarters · filed 2026-03-24 | $39.08M derived: sum of 3 quarters · filed 2026-08-05 | $61.98M 10-K · filed 2026-03-24 |
| 2025-09-30 | $14.40M 10-Q · filed 2025-11-04 | $30.97M derived: sum of 2 quarters · filed 2026-08-05 | $53.86M 10-Q · filed 2025-11-04 | $79.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $16.57M 10-Q · filed 2026-08-05 | $39.46M 10-Q · filed 2026-08-05 | $64.70M derived: sum of 3 quarters · filed 2026-08-05 | $91.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $22.90M 10-Q · filed 2026-05-11 | $48.14M derived: sum of 2 quarters · filed 2026-05-11 | $75.38M derived: sum of 3 quarters · filed 2026-05-11 | $107.21M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $25.24M 10-K · filed 2025-03-31 | $52.48M derived: sum of 2 quarters · filed 2025-11-04 | $84.31M derived: sum of 3 quarters · filed 2025-11-04 | $118.08M 10-K · filed 2026-03-24 |
| 2024-09-30 | $27.24M 10-Q · filed 2025-11-04 | $59.07M derived: sum of 2 quarters · filed 2025-11-04 | $92.84M 10-Q · filed 2025-11-04 | $123.71M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $31.82M 10-Q · filed 2025-08-05 | $65.60M 10-Q · filed 2025-08-05 | $96.47M derived: sum of 3 quarters · filed 2025-08-05 | $121.81M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $33.78M 10-Q · filed 2025-05-05 | $64.64M derived: sum of 2 quarters · filed 2025-05-05 | $89.99M derived: sum of 3 quarters · filed 2025-05-05 | $111.93M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $30.87M 10-K · filed 2025-03-31 | $56.21M derived: sum of 2 quarters · filed 2025-03-31 | $78.15M derived: sum of 3 quarters · filed 2025-03-31 | $102.55M 10-K · filed 2026-03-24 |
| 2023-09-30 | $25.35M 10-K · filed 2025-03-31 | $47.28M derived: sum of 2 quarters · filed 2025-03-31 | $71.68M 10-Q · filed 2024-10-29 | $92.22M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $21.94M 10-K · filed 2025-03-31 | $46.33M 10-Q · filed 2024-07-31 | $66.87M derived: sum of 3 quarters · filed 2025-03-31 | $85.11M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $24.39M 10-K · filed 2025-03-31 | $44.93M derived: sum of 2 quarters · filed 2025-03-31 | $63.18M derived: sum of 3 quarters · filed 2025-03-31 | $75.76M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $20.54M 10-K · filed 2024-03-28 | $38.78M derived: sum of 2 quarters · filed 2024-03-28 | $51.36M derived: sum of 3 quarters · filed 2024-03-28 | $62.71M 10-K · filed 2025-03-31 |
| 2022-09-30 | $18.24M 10-K · filed 2024-03-28 | $30.82M derived: sum of 2 quarters · filed 2024-03-28 | $42.17M 10-Q · filed 2023-10-30 | $53.26M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $12.58M 10-K · filed 2024-03-28 | $23.93M 10-Q · filed 2023-07-31 | $35.02M derived: sum of 3 quarters · filed 2024-03-28 | $42.91M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $11.35M 10-K · filed 2024-03-28 | $22.44M derived: sum of 2 quarters · filed 2024-03-28 | $30.32M derived: sum of 3 quarters · filed 2024-03-28 | $35.55M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $11.09M 10-K · filed 2023-03-28 | $18.97M derived: sum of 2 quarters · filed 2023-03-28 | $24.20M derived: sum of 3 quarters · filed 2023-03-28 | $28.00M 10-K · filed 2024-03-28 |
| 2021-09-30 | $7.89M 10-K · filed 2023-03-28 | $13.11M derived: sum of 2 quarters · filed 2023-03-28 | $16.91M 10-Q · filed 2022-11-07 | $19.24M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $5.22M 10-K · filed 2023-03-28 | $9.02M 10-Q · filed 2022-08-01 | $11.35M derived: sum of 3 quarters · filed 2023-03-28 | $12.14M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $3.80M 10-K · filed 2023-03-28 | $6.13M derived: sum of 2 quarters · filed 2023-03-28 | $6.92M derived: sum of 3 quarters · filed 2023-03-28 | $7.13M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $2.33M 10-K · filed 2022-02-28 | $3.12M derived: sum of 2 quarters · filed 2022-02-28 | $3.34M derived: sum of 3 quarters · filed 2022-02-28 | $3.67M 10-K · filed 2023-03-28 |
| 2020-09-30 | $789.00K 10-K · filed 2022-02-28 | $1.00M derived: sum of 2 quarters · filed 2022-02-28 | $1.34M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $216.00K 10-K · filed 2022-02-28 | $550.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $334.00K 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $1.09M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |